CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
LEO 29102 cream +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00875277
NCT00875277Phase 2Completed

A Psoriasis Plaque Test Comparing LEO 29102 Cream and Its Different Combinations to Daivobet® Ointment and a Vehicle Control for the Treatment of Psoriasis Vulgaris

LEO Pharma·interventional·Posted Apr 3, 2009·Updated Mar 12, 2025

In Brief

A Phase 2 clinical trial evaluating LEO 29102 cream, LEO 29102 Cream Vehicle, and 4 other interventions for Psoriasis Vulgaris. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this trial is to evaluate the anti-psoriatic effect of LEO 29102 cream and its combination with calcipotriol and betamethasone using a psoriasis plaque test method.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 3, 2009
Enrollment StartApr 1, 2009
Primary CompletionMay 1, 2009
Study CompletionJul 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.2 years ago

Interventions

LEO 29102 creamdrug

LEO 29102 Cream Vehicledrug

Betamethasone Dipropionate Creamdrug

LEO 29102 Plus Calcipotriol Creamdrug

LEO 29102 Plus Betamethasone Dipropionatedrug

Daivobet® Ointmentdrug